Adaptive Biotechnologies (ADPT) Tops Q3 EPS by 2c; Reports Cash and Cash Equivalents of $632.4M

Adaptive Biotechnologies (NASDAQ: ADPT) reported Q3 EPS of ($0.40), $0.02 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $39.5 million versus the consensus estimate of $36.64 million.

GUIDANCE:

Adaptive Biotechnologies sees FY2021 revenue of $148-155 million, versus the consensus of $152 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.

You May Also Be Interested In

• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• BofA lists top 5 themes driving next $1tn in incremental semi sales